First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Accent Therapeutics
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
Marengo Therapeutics, Inc.
Assistance Publique - Hôpitaux de Paris
Fate Therapeutics
Incyte Corporation
Incyte Corporation